Voyager Therapeutics
M$165
42
+M$0+0% Wednesday 19:10
Statistiche
In rialzo oggi
165
In ribasso oggi
165
In rialzo da 52 settimane
167
In ribasso da 52 settimane
130
Volume
40
Volume medio
46
Cap. di mercato
7.18B
Rapporto P/E
-
Rendimento da dividendi
-
Dividendo
-
Prossimamente
Guadagni
5NovAtteso
EPS attesi
-0.485867
EPS effettivi
N/D
Le persone seguono anche
Questo elenco si basa sulle watchlist delle persone su Stock Events che seguono VYGR.MX. Non rappresenta una raccomandazione d'investimento.
Concorrenti
Questo elenco è un'analisi basata su recenti eventi di mercato. Non è una raccomandazione di investimento.
Biogen
BIIB
Cap. di mercato29.83B
Bluebird bio
BLUE
Cap. di mercato108.22M
Sarepta Therapeutics
SRPT
Cap. di mercato12.95B
PTC Therapeutics
PTCT
Cap. di mercato2.72B
Novartis
NVS
Cap. di mercato244.75B
Pfizer
PFE
Cap. di mercato164.39B
Abeona Therapeutics
ABEO
Cap. di mercato246.89M
Info
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Robert W. Hesslein
Dipendenti
101
Paese
United States
ISIN
US92915B1061